Articles by Hiten D. Patel, MD, MPH
These results formed the basis for the FDA’s approval of enzalutamide for the treatment of patients with mHSPC.
Dr. Michael S Hofman reported findings from the phase 2 TheraP (ANZUP 1603) clinical trial.
The results came from the open-label, phase 4 CARD trial.
Dr. Sumanta K. Pal et al, reported the results of the study comparing three MET inhibitors with sunitinib in pRCC.
Efortumab vedotin prolonged OS in patients who had previously received chemotherapy and checkpoint inhibitors.
The phase 3 CLEAR trial showed improved OS for lenvatinib plus pembrolizumab as first-line therapy for advanced RCC.
Nivolumab improves disease-free survival, non-urothelial tract recurrence-free survival, and metastasis-free survival.
The phase 2 SWOG 1500 trial showed improvement in progression-free survival for cabozantinib in metastatic papillary RCC.
Relugolix represents a new oral option for GnRH receptor antagonism.
Establishing Cabazitaxel as third-line therapy for metastatic castration-resistant prostate cancer by the phase 4 CARD trial.
177Lu-PSMA-617 was able to generate more PSA responses of at least 50% reduction compared to taxane cabazitaxel in mCRPC.
Adding enzalutamide to androgen deprivation therapy improved progression-free survival in hormone-sensitive prostate cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.